Altimmune Inc at Jefferies Healthcare Conference Transcript
Okay. Welcome, everyone. Day three, last day, 2023 Jefferies Healthcare Conference. My name is Roger Song, one of the senior analyst who covers SMID-cap biotech here and our next presenting company is Altimmune.
With me today is CEO, Vipin, and CMO, Scott. Good to see you.
Good to see you too.
Okay. Maybe just get the start, Vipin, maybe you can give us updated elevator pitch for folks even they already know about Altimmune or particularly for the people new to the story.
Absolutely. Well, first of all, thank you for inviting us and excited to be here. So at Altimmune, we are developing peptide-based therapeutics for obesity and for liver diseases. We've got our lead program is a GLP-1 glucagon dual receptor agonist that we're developing for obesity and for NASH.
For
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |